

06

MAY 2021

Thursday

WEBINAR

via Webex*

45' (talk) + 30' (discussion)

3.00 - 4.15pm



Antibody responses to SARS-CoV-2 infection and vaccination

ABSTRACT

SARS-CoV-2 has emerged in late 2019 in China and has since then caused a severe pandemic. Early on in the outbreak we have developed serological assays to explore the antibody response to the virus and specifically against its spike protein. So far we have shown that the vast majority of infected individuals, even if only suffering from mild infection, induces robust antibody titers. Titers measured in these binding assays against the spike protein correlate well with neutralizing activity against authentic SARS-CoV-2. While we expect moderate waning of antibodies over time, we have shown that antibody levels are relatively stable over at least 5 months. Studies to characterize long-term antibody kinetics and correlates of protection have been initiated in April of 2020 and are expected to continue for at least 24 months. In addition, we are studying the immune response to SARS-CoV-2 mRNA vaccination on a polyclonal and monoclonal level both in naïve individuals and in individuals who already had experienced SARS-CoV-2 infections.



SPEAKER

Prof Florian KRAMMER

Professor, Department of Microbiology,
Icahn School of Medicine at Mount Sinai

HOST:

Department of Infection and Immunity (LIH)

RESPONSIBLE LIH SCIENTIST:

Prof Dirk Brenner / (dirk.brenner@lih.lu)

www.lih.lu

Supported by:



Fonds National de la
Recherche Luxembourg

***To join the Webinar:**

JOIN

Event number: **183 403 5096**

Event password: **cQf6sph2m8P**